Online CME

Series Activities

Series Activities

Cleveland Clinic Tumor Boards

Current and Future Treatment
Options for Advanced Melanoma

Print this Content

Release Date: February 25, 2016
Renewal Date: February 25, 2017
Expiration Date: February 25, 2018

Estimated Time of Completion: 1 hour 15 minutes

Description

This webcast focuses on current progress in the treatment of patients with advanced melanoma. The multidisciplinary faculty present various aspects of the case, including radiolologic imaging, pathologic findings, mutation testing, risk assessment and treatment. Suggested treatment options are based on best practices, current treatment guidelines, and emerging clinical trial data on treatment of localized and metastatic disease. Choice of targeted agents, predictive markers, and use of immunotherapy for unresectable disease are also presented.

Learning Objectives

  1. Discuss indications for and potential benefits for surgery for patients with locoregional melanoma or metastatic disease, and following neoadjuvant therapy.
  2. Identify those patients who could benefit from radiotherapy, and which type of radiotherapy is best suited for a given patient.
  3. Summarize results from trials using targeted agents for advanced melanoma, such as small-molecule tyrosine kinase inhibitors.
  4. Differentiate between various immunotherapies for advanced melanoma in terms of mechanism of action, and cite efficacy results from key clinical trials.

Target Audience

This activity is designed for health care practitioners including medical oncologists, surgical oncologists, dermatologists, pathologists, and other health care professionals who manage patients with melanoma.

Accreditation

The Cleveland Clinic Foundation Center for Continuing Education is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

The Cleveland Clinic Foundation Center for Continuing Education designates this enduring material for a maximum of 1.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Participants claiming CME credit from this activity may submit the credit hours to the American Osteopathic Association for Category 2 credit.

Activity Director and Faculty

Activity Directors
Jame Abraham, MD

Jame Abraham, MD
Director, Breast Oncology Program at Taussig Cancer Institute
Co-Director of the Cleveland Clinic Multidisciplinary Breast Cancer Program
Cleveland Clinic
Cleveland, OH

Marc S. Ernstoff, MD
Department of Hematology and Oncology
Cleveland Clinic
Cleveland, OH

Faculty

Michael Atkins, MD
Deputy Director, Georgetown-Lombardi Comprehensive Cancer Center
Professor of Oncology and Medicine (Hematology/Oncology)
Georgetown University School of Medicine
Washington, DC

Steven Billings, MD
Department of Anatomic Pathology
Cleveland Clinic
Cleveland, OH

Brian Gastman, MD
Department of Plastic Surgery
Cleveland Clinic
Cleveland, OH

John Kirkwood, MD
Usher Professor of Medicine, Dermatology & Translational Science
Director, Melanoma and Skin Cancer Program
University of Pittsburgh
Pittsburg, PA

Roger Klein, MD, JD
Department of Molecular Pathology
Cleveland Clinic
Cleveland, OH

Vern Sondak, MD
Chair, Department of Cutaneous Oncology
Director of Surgical Education
H. Lee Moffitt Cancer Center and Research Institute
Tampa, FL

Jennifer Yu, MD
Department of Radiation Oncology
Cleveland Clinic
Cleveland, OH

CME Disclaimer

The information in this educational activity is provided for general medical education purposes only and is not meant to substitute for the independent medical judgment of a physician relative to diagnostic and treatment options of a specific patient's medical condition. The viewpoints expressed in this CME activity are those of the authors/faculty. They do not represent an endorsement by The Cleveland Clinic Foundation. In no event will The Cleveland Clinic Foundation be liable for any decision made or action taken in reliance upon the information provided through this CME activity.

Disclosures

In accordance with the Standards for Commercial Support issued by the Accreditation Council for Continuing Medical Education (ACCME), The Cleveland Clinic Foundation Center for Continuing Education requires resolution of all faculty conflicts of interest to ensure CME activities are free of commercial bias.

The following faculty have indicated that they may have a relationship, which in the context of their presentations, could be perceived as a potential conflict of interest:

Michael Atkins, MD
  Amgen; Genentech/Roche; Merck; Norvartis Oncology Consulting
  Bristol-Myers Squibb Co. Consulting; Other activities from which remuneration is received or expected: Nivolumab and ipilimumab
Vernon K. Sondak, MD
  Amgen; Merck; OncoSec; Genentech; Navidea Biopharmaceuticals; Provectus Consulting; Membership on advisory committee or review panels
  Bristol-Myers Squibb Co.; GlaxoSmithKline; Novartis Consulting; Membership on advisory committee or review panels; Data Safety Monitoring Board
  Polynoma Data Safety Monitoring Board

The following faculty have indicated they have no relationship which, in the context of their presentations, could be perceived as a potential conflict of interest:

Jame Abraham, MD
Steven Billings, MD
Marc Ernstoff, MD
Brian Gastman, MD
John Kirkwood, MD
Roger Klein, MD
Jennifer Yu, MD, PhD

All other planners, CME staff, and content reviewers, have no relevant financial relationships to disclose.

The Cleveland Clinic Foundation Center for Continuing Education acknowledges an educational grant for support of this activity from:

Novartis Pharmaceuticals Corporation

This CME activity was produced by Cleveland Clinic Foundation Center for Continuing Education,
Taussig Cancer Institute and Harborside Press.